2 completed, 2 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow E5564: new trials by email Literature Review of E5564 trials Research Report on E5564
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects Eritoran, D5W - Insulin Sensitivity | Phase 2 | Terminated | The University of Texas Health Science Center at San Antonio | 15 | 2015-01-01 | 2020-03-04 |
| The Role of TLR4 on Lipid-induced Insulin Resistance Eritoran, D5W (5% Dextrose in water) - Insulin Sensitivity | Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 10 | 2015-01-01 | 2019-10-08 |
| A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors E5564 - Leukemia | Phase 1 | Terminated | Eisai Inc. | 30 | 2008-09-01 | 2014-07-11 |
| A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis E5564 - Sepsis, Shock, Septic | Phase 2 | Completed | Eisai Inc. | 300 | 2001-10-01 | 2005-12-12 |
Insulin Resistance (2) · Endotoxemia (1) · Graft vs Host Disease (1) · Infections (1) · Leukemia (1) · Sepsis (1) · Shock (1) · Shock, Septic (1) · Systemic Inflammatory Response Syndrome (1)
Eisai Inc. (2) · The University of Texas Health Science Center at San Antonio (2)
United States (4)
Nicolas Musi, MD (2) · Alec Wittek, M.D. (1) · Kenneth Cooke (1)